HM61713: Updated Phase I/II data

Updated data from the open-label, South Korean Phase I/II HM-EMSI-101 trial in 70 patients with T790M EGFR mutation-positive NSCLC who developed resistance to previous EGFR TKIs showed that once-daily 800 mg oral HM61713 led to an ORR of 62% and a DCR of 91%. The median duration of response has not yet been reached. Data were presented at the ESMO Asia 2015 meeting in Singapore. Interim data from the trial were reported last year (see BioCentury, June 15, 2015). ...